David Bullock, MD
Family Medicine · Mount Vernon, KYNPI 1912058272
Payments from drug & device makers
Across 158 payments — averaging $14.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$298
- Pfizer$224
- AbbVie$221
- Kowa Pharmaceuticals America, Inc.$205
- Astellas Pharma US Inc$143
- Novo Nordisk$118
- plus $1K from 25 others
What the payments were for
- Food & beverage$2,323100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 20 | $298 |
| Pfizer | 22 | $224 |
| AbbVie | 11 | $221 |
| Kowa Pharmaceuticals America, Inc. | 16 | $205 |
| Astellas Pharma US Inc | 9 | $143 |
| Novo Nordisk | 8 | $118 |
| Abbott | 6 | $111 |
| Insulet Corporation | 8 | $109 |
| E.r. Squibb & Sons, L.L.C. | 7 | $89 |
| Mannkind Corporation | 5 | $77 |
| Lilly USA, LLC | 5 | $76 |
| Otsuka America Pharmaceutical, Inc. | 4 | $75 |
| GSK | 5 | $69 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $56 |
| Dexcom, Inc. | 1 | $49 |
| AstraZeneca | 3 | $48 |
| Amgen | 2 | $40 |
| Axsome Therapeutics, Inc. | 2 | $38 |
| Merck | 3 | $36 |
| Sunovion Pharmaceuticals Inc. | 3 | $35 |
| Daiichi Sankyo Inc. | 2 | $34 |
| Novartis | 2 | $29 |
| Boehringer Ingelheim | 2 | $26 |
| Paratek Pharmaceuticals, Inc. | 1 | $17 |
| Lundbeck LLC | 1 | $17 |
| Neurelis, Inc. | 1 | $15 |
| Mylan Specialty L.p. | 1 | $15 |
| Sanofi Pasteur Inc. | 1 | $14 |
| Evoke Pharma, Inc. | 1 | $14 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
| Corcept Therapeutics | 1 | $11 |
How this compares
$2,323 in reported general payments places this provider in the 70th percentile of 1,559 family medicine providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 273 | $321,836 |
| EliquisApixaban | 241 | $212,797 |
| JardianceEmpagliflozin | 214 | $207,605 |
| MounjaroTirzepatide | 142 | $166,339 |
| JanuviaSitagliptin Phosphate | 149 | $128,032 |
| LinzessLinaclotide | 131 | $102,157 |
| EntrestoSacubitril/Valsartan | 113 | $96,676 |
| IngrezzaValbenazine Tosylate | 11 | $90,036 |
| TrulicityDulaglutide | 53 | $85,155 |
| RinvoqUpadacitinib | 12 | $79,490 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 94 | $70,240 |
| FarxigaDapagliflozin Propanediol | 71 | $68,007 |
| XareltoRivaroxaban | 61 | $59,564 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 14 | $42,068 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 44 | $35,203 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $118 | $321,836273 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Tradjenta, Combivent Respimat | $26 | $276,459290 claims |
| Lilly USA, LLCMounjaro, Trulicity | $76 | $251,494195 claims |
| PfizerEliquis | $224 | $212,797241 claims |
| AbbVieLinzess, Rinvoq, Vraylar | $221 | $196,669154 claims |
| MerckJanuvia | $36 | $128,032149 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort, Brilinta | $48 | $122,107166 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $69 | $110,299157 claims |
| NovartisEntresto | $29 | $96,676113 claims |
| Johnson & JohnsonXarelto | $298 | $59,56461 claims |
| Astellas Pharma US IncMyrbetriq | $143 | $28,60938 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $75 | $20,38812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,559 family medicine providers in Kentucky.
Other family medicine in Mount Vernon
- Brian SmithVersailles$7.7M
- Barbara Fleming-PhillipsLexington$1.4M
- Christopher RhyneLouisville$1M
- Kruti PatelBurlington$463K
- Michael LovelaceLouisville$244K
- John RichardLexington$226K
- Diego MastronardiBowling Green$196K
- James TurnboPaducah$124K
- Eleida Tur OlivaLexington$113K
- Jeffrey GreenParis$103K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.